EGF +61 A>G polymorphism predicts complete pathologic response independent of KRAS status in locally advanced rectal cancer patients undergoing neoadjuvant cetuximab-based chemoradiation

Daniel Vallböhmer, Siwen Hu-Lieskovan, Peter Grimminger, Jan Brabender, Arnulf H. Hölscher, Robert Semrau, Dirk Arnold, Jean-Pascal Machiels, Claus Rödel, Vaneja Velenik & Heinz-Josef Lenz
Introduction: Cetuximab has demonstrated significant clinical activity in metastatic colon cancer. However, cetuximab-containing neoadjuvant chemoradiation has not been shown to improve local control or survival in locally advanced rectal cancer patients in recent phase I/II trials. In order to[for full text, please go to the a.m. URL]